CCEL logo

CRYO-CELL INTL INC

CCELNYSE AMERICAN
🏆 #4371 by market capEarnings Feb 25US Equity
$5.10▲ $0.60 (+13.21%)
Pre-market · at close
🔔
Track CCEL
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 13.2%
7d▲ 13.2%
14d▲ 22.9%
30d▲ 21.6%
ytd▲ 47.8%
1y▲ 14.1%
🏦Market Cap
$41M
Small Cap
📈Revenue Growth (YoY)
-1.3%
Declining
📊Gross Margin
78.0%
High
💵FCF Margin
14.9%
Healthy
⚖️P/S Ratio
1.3x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$4.53 – $5.10
52-Week Range
$2.72 – $5.20
Volume (shares)
305
Avg Volume (shares)
—
Shares Outstanding
8.1M
Next Earnings
2027-02-25

Fundamentals Snapshot

Annual Revenue
$32M
Last Q Revenue
$8M
P/E Ratio
-22.1
P/S Ratio
1.3x
EPS (TTM)
$-0.35
Dividend Yield
0.00%
Dilution (1yr)
−1.8%
CCEL logo

CRYO-CELL INTL INC

CCEL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$32M▼ −1.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
76.6%▲ +2.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$5M▲ +39.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$5M▲ +118.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
8.1M▼ −1.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$11M▲ +$1M YoY
StockOtter · stockotter.space

About CRYO-CELL INTL INC

Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Sell
6 analysts
Strong Buy0
Buy0
Hold3
Sell1
Strong Sell2
Ratings as of Oct 2026

Latest News & Updates

News unavailable.